文献速递介入妇产影像腹部MR

腹壁子宫内膜异位症经皮冷冻消融后的长期结局

Long-term outcomes after percutaneous cryoablation of abdominal wall endometriosis.
PubMed 文献 · Eur Radiol · 2024-03-21

回顾性观察40例共52个有症状腹壁子宫内膜异位症结节,2013年1月至2022年5月行冷冻消融,随访至少12个月,中位随访40.5个月。首次冷冻消融后3个月80%(32/40)患者疼痛完全缓解,且与MRI无残留结节相关;36个月和60个月无痛生存率分别为89.2%和76.8%,长期无重大不良事件。

要点

  • 首次冷冻消融后3个月80%(32/40)患者疼痛完全缓解,与MRI无残留子宫内膜异位结节相关。
  • 中位无痛生存率36个月为89.2%(95%CI 70.1-96.4%),60个月为76.8%(95%CI 55.3-83.8%)。
  • 长期未报告重大不良事件或副作用。

核心结论

  • 冷冻消融可安全有效地为腹壁子宫内膜异位症结节患者提供长期疼痛缓解。

研究设计与样本

  • 回顾性观察性研究,纳入40例连续患者共52个有症状腹壁子宫内膜异位症结节,中位年龄37岁(IQR 32-40岁),2013年1月至2022年5月行冷冻消融,随访至少12个月;采用视觉模拟量表评估疼痛,并行MRI评估,无痛生存率用Kaplan-Meier法计算,不良事件按欧洲心血管与介入放射学会分类系统分级。

关键影像表现/征象

  • 首次冷冻消融后3个月80%(32/40)患者疼痛完全缓解,且与MRI上无残留子宫内膜异位结节相关。
  • 未发现患者或病灶特征可预测治疗失败。

诊断标准与关键数值

  • 冷冻消融前中位VAS评分为8分(IQR 7-9)。
  • 中位无痛生存率36个月为89.2%(95%CI 70.1-96.4%),60个月为76.8%(95%CI 55.3-83.8%)。

临床应用与阅片要点

  • 原文结论为冷冻消融可安全有效地为腹壁子宫内膜异位症结节患者提供长期疼痛缓解。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To retrospectively evaluate the long-term outcomes after percutaneous cryoablation of abdominal wall endometriosis (AWE).

METHOD: The Institutional Review Board approved this retrospective observational review of 40 consecutive patients, of a median age of 37 years (interquartile range [IQR] 32-40 years), presenting with a total of 52 symptomatic AWE nodules. All patients underwent cryoablation between January 2013 and May 2022 with a minimum follow-up period of 12 months. Outcomes were assessed using a visual analog scale (VAS) that measured pain, as well as by magnetic resonance imaging (MRI). The pain-free survival rates were derived using the Kaplan-Meier estimator. Adverse events were analyzed and graded using the classification system of the Cardiovascular and Interventional Radiological Society of Europe.

RESULTS: The median follow-up time was 40.5 months (IQR 26.5-47.2 months). The median VAS score before cryoablation was 8 (IQR 7-9). Complete relief of symptoms was documented in 80% (32/40) of patients at 3 months after initial cryoablation and correlated with the absence of residual endometriosis nodules on MRI. The median pain-free survival rates were 89.2% [95% CI, 70.1-96.4%] at 36 months and 76.8% [95% CI, 55.3-83.8%] after 60 months. No patient or lesion characteristics were found to be prognostic of failure. No major adverse events or side effects were reported in long term.

CONCLUSION: Cryoablation safely and effectively afforded long-term pain relief for patients with AWE nodules.

CLINICAL RELEVANCE STATEMENT: AWE cryoablation was found to be safe and effective in the long-term.

KEY POINTS: • Cryoablation is highly effective with 80% of patients experiencing complete relief of AWE symptoms after a single procedure. • Cryoablation is safe without long-term adverse events or side effects. • The median pain-free survival rates are 89.2% at 36 months and 76.8% at 60 months.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Marcelin C, Maas P, Jambon E, et al. Long-term outcomes after percutaneous cryoablation of abdominal wall endometriosis. Eur Radiol. 2024. PMID: 38512491. doi:10.1007/s00330-024-10689-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。